FAQ on Lantern Pharma's AI Tool for Predicting Blood-Brain Barrier Permeability

What is predictBBB.ai(TM)?

predictBBB.ai(TM) is a public AI module developed by Lantern Pharma that predicts the blood-brain barrier (BBB) permeability of small molecules with 94% accuracy, 95% sensitivity, and 89% specificity.

Why is predictBBB.ai(TM) significant?

It addresses the pharmaceutical challenge where only 2–6% of small molecules can cross the BBB, and it ranks among the top performers on the Therapeutic Data Commons Leaderboard, leveraging synthetic data augmentation and advanced molecular representation.

How does predictBBB.ai(TM) work?

The platform is built on billions of molecular data points from Lantern’s proprietary data lake and processes compounds in real time using synthetic data augmentation and advanced molecular representation.

Who developed predictBBB.ai(TM)?

predictBBB.ai(TM) was developed by Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug development company.

What is the market potential for BBB technologies?

The BBB technologies market is projected to grow from $1.4 billion in 2023 to $9.85 billion by 2032, indicating strong clinical demand.

Where can I find more information about Lantern Pharma?

More information about Lantern Pharma is available in the company’s newsroom at https://ibn.fm/LTRN.

What are the implications of predictBBB.ai(TM) for drug development?

predictBBB.ai(TM) could significantly accelerate and reduce the cost of oncology drug discovery and development by accurately predicting which small molecules can cross the BBB, a critical step in treating brain-related diseases.

How does predictBBB.ai(TM) compare to other methods?

predictBBB.ai(TM) is among the top performers on the Therapeutic Data Commons Leaderboard, indicating its superior accuracy and efficiency compared to other methods.

What should investors know about Lantern Pharma?

Investors should note that Lantern Pharma is transforming oncology drug discovery with its AI and machine learning platform, RADR(R), and has a pipeline of innovative product candidates with a combined annual market potential of over $15 billion USD.